Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07135491
ABSTRACT:
The present invention relates to 5-Aryltetrazole Compounds, compositions comprising an effective amount of a a 5-Aryltetrazole Compound, and methods for treating an inflammation disease, a reperfusion disease, or hyperuricemia in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
REFERENCES:
patent: 5049572 (1991-09-01), Scherrer et al.
patent: 5232937 (1993-08-01), Makovec et al.
patent: 5284954 (1994-02-01), Wittenberger
patent: 5364869 (1994-11-01), De et al.
patent: 5663357 (1997-09-01), Teng et al.
patent: 5874593 (1999-02-01), Ushio
patent: 5976576 (1999-11-01), Makovec et al.
patent: 6191136 (2001-02-01), Marban
patent: 6191289 (2001-02-01), Ushio
patent: 6277998 (2001-08-01), Ushio
patent: 6281222 (2001-08-01), Salzman et al.
patent: 6297261 (2001-10-01), Christopherson et al.
patent: 6388088 (2002-05-01), Sidduri
patent: 6417393 (2002-07-01), Christopherson et al.
patent: 6569862 (2003-05-01), Marban
patent: 6696479 (2004-02-01), Van Der Schaaf et al.
patent: 6706749 (2004-03-01), Dahl et al.
patent: 2002/0032210 (2002-03-01), Dahl et al.
patent: 2002/0037905 (2002-03-01), Dahl et al.
patent: 2002/0103202 (2002-08-01), Pinto et al.
patent: 2003/0186998 (2003-10-01), Marban
patent: 2003/0229120 (2003-12-01), Olsen et al.
patent: 2004/0019208 (2004-01-01), Nivorozhkin et al.
patent: 0638553 (1994-07-01), None
patent: 10025294 (1998-01-01), None
patent: WO 90/09989 (1990-09-01), None
patent: WO 93/16053 (1993-08-01), None
patent: WO 98/58522 (1998-12-01), None
patent: WO 99/24038 (1999-05-01), None
patent: WO 99/24442 (1999-05-01), None
patent: WO 00/16798 (2000-03-01), None
patent: WO 00/24707 (2000-05-01), None
patent: WO 00/28979 (2000-05-01), None
patent: WO 00/64888 (2000-11-01), None
patent: WO 01/66098 (2001-09-01), None
patent: WO 01/85705 (2001-11-01), None
patent: WO 02/00647 (2002-01-01), None
Oda et al., Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD, Science. May 26, 1989;244(4907):974-6.
Tan et al. ,Xanthine oxidase activity in the circulation of rats following hemorrhagic shock, Free Radic Biol Med. Oct. 1993; 15(4):407-14.
McCord J.M., Oxygen-derived free radicals in postischemic tissue injury, N Engl J Med. Jan. 17, 1985;312(3):159-63
Miesel et al., “Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood”,Inflammation. Dec. 1994;18(6):597-612.
Engerson et al., Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues,J Clin Invest. Jun. 1987;79(6):1564-70.
Akaide et al., Dependance on O2- generation by xanthine oxidase of pathogenesis of influenza virus infection in mice,J Clin Invest. Mar. 1990;85(3):739-45.
Ketai et al., Plasma hypoxanthine and exercise.Am Rev Respir Dis.Jul. 1987; 136(1):98-101.
Mohacsi et al., Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in respose to various stimuli, Biochim Biophys Acta. Aug. 23, 1996;1316(3):210-6.
Friedl et al. Ischemia-reperfusion in humans. Apperance of xanthine oxidase activity. Am J Pathol. Mar. 1990;136(3):491-5.
Friedl et al., Roles of histamine, complement and xanthine oxidase in thermal injury of skin.Am J Pathol. Jul. 1989;135(1):203-17.
Parks et al., Role of oxygen free radicals in shock, ischemia, and organ preservation.Surgery. Sep. 1983;94(3):428-32.
Demling et al., Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes.Am Rev Respir Dis. Nov. 1992;146(5 Pt 1):1272-8.
Chambers et al., Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol. Feb. 1985;17(2):145-52.
Deitch et al., Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation.Surgery. Aug. 1988;104(2):191-8.
Mayumi et al., Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock. May 1996;5(5):324-32.
Flynn et al., Allopurinol plus strandard resuscitation preserves hepatic blood flow and function following hemorrhagic shock.J Trauma. Dec. 1994;37(6):956-61.
Zollei, I., Experimental study of hypovolaemic shock-induced gastric mucosal lesions in the rat. Ann Acad Med Singapore. Jan. 1999;28(1):85-9.
Modelska et al., Inhibition of beta-adrenergic-dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock. Am J. Physiol. May 1999;276(5 Pt 1):L844-57.
Flynn et al., Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function. J Surg Res. Mar. 1997;68(2):175-80.
Mannion et al., Role of xanthine oxidase inhibition in survival from hemorrhagic shock. Circ Shock. Jan. 1994;42(1):39-43.
Cunningham and Keaveny, Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock. Eur Surg Res. 1978;10(5):305-13.
Youn et al., Oxidants and the pathophysiology of burn and smoke inhalation injury. Free Radic Biol Med. 1992;12(5):409-15.
Deitch et al., A study of the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation.J Trauma. Feb. 1992;32(2):141-7.
Anderson et al., Hypovolemic shock promotes neutrophil sequestration in lungs by a xanthine oxidase-related mechanism. J Appl Physiol. Nov. 1991;71(5):1862-5.
Pogetti et al., Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma. Jun. 1992;32(6):723-7; discussion 727-8.
Nielsen et al., Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg. Sep. 1995;110(3):715-22.
Schwartz et al., Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol. Apr. 1995;12(4):434-40.
Crowell et al., Effect of allopurinol on hemorrhagic shock. Am J Physiol. Apr. 1969;216(4):744-8.
Linder et al., Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. Aug. 1999;79(8):967-74.
Saksela et al., Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol Neonate. Oct. 1998;74(4):274-80.
Battelli et al., Determination of xanthine oxidase in human serum by a competitive enzyme-linked mmunosorbent assay (ELISA). Clin Chim Acta. Mar. 1999;281(1-2):147-58.
Houston et al., Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. Feb. 19, 1999;274(8):4985-94.
Fox et al., Immunohistochemical localization of xanthine oxidase in human retina. Free Radic Biol Med. Apr. 1998;24(6):900-5.
Rouquette et al., Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett. Apr. 24, 1998;426(3):397-401.
Cardillo et al., Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. Jul. 1997;30(1 Pt 1):57-63.
Page et al., Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. Jul. 23, 1998;1381(2):191-202.
Zhang et al., Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. Biochem Biophys Res Commun. Aug. 28, 1998;249(3):767-72
Trujillo et al., Xanthine oxidase-mediated decomposition of S-nitrosothils. J Biol Chem. Apr. 3, 1998;273(14):7828-34.
Goldfinger, S.E., Treatment of gout. N Engl J Med. Dec. 2, 1971;285(23):1303-6.
Buchanan et al., Hypocholesterolemic 5-substituted tetrazoles. J Med Chem. Nov. 1969;12(6):1001-6.
Shu
Nivorozhkin Alex
Ram Siya
Salzman Andrew
Southan Garry
Szabo Csaba
Inotek Pharmaceuticals Corp.
Solola Taofiq
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
5-Aryltetrazole compounds and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-Aryltetrazole compounds and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-Aryltetrazole compounds and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3623210